PMV Pharmaceuticals has reported a 43% response rate in a midphase ovarian cancer trial, putting the biotech on a track it believes will lead to a filing for FDA approval in the first quarter of 2027.

Premier Investments (ASX:PMV) has had a rough three months with its share price down 31%. But if you pay close attention, you might find that its key financial indicators look quite decent, which ...

Confirmed responses were observed in patients whose tumors were TP53 Y220C mutated and KRAS wild-type in eight tumor types, including ovarian, lung, breast, endometrial, head and neck, colorectal, ...

PMV Pharma is laying off 30% of its staff as the precision oncology biotech prioritizes pushing its lead solid tumor candidate toward a phase 2 trial in the coming months. The drug, PC14586, became ...

PRINCETON, N.J., Oct. 23, 2024 (GLOBE NEWSWIRE) -- PMV Pharmaceuticals, Inc. (Nasdaq: PMVP), a precision oncology company pioneering the discovery and development of small molecule, tumor-agnostic ...

Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. PMV Pharmaceuticals ( (PMVP)) has ...

The investment seeks long-term capital appreciation. Under normal market conditions, the fund invests at least 80% of its net assets (plus any borrowings for investment purposes) in equity securities ...

PMV Pharmaceuticals, Inc., a precision oncology company, engages in the discovery and development of small molecule and tumor-agnostic therapies for p53 mutations in cancer. It’s lead product ...

Entering text into the input field will update the search result below Entering text into the input field will update the search result below ...